{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:07:45Z","timestamp":1787836065599,"version":"build-2784847793"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T00:00:00Z","timestamp":1749772800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T00:00:00Z","timestamp":1749772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s00535-025-02266-4","type":"journal-article","created":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T13:20:20Z","timestamp":1749820820000},"page":"1079-1090","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Asia Pacific Gastroesophageal Cancer Congress (APGCC) 2024 consensus statement on stage 2 and 3 locally advanced gastric and Siewert 3 junctional adenocarcinoma"],"prefix":"10.1007","volume":"60","author":[{"given":"Yoshio","family":"Masuda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang Ler","family":"Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danson","family":"Yeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charleen","family":"Yeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koy Min","family":"Chue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Said Bani","family":"Araba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiew Woon","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baldwin","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"June","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinlin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claramae","family":"Chia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kennedy","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Samol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daryl","family":"Chia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun Liang","family":"Teh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghav","family":"Sundar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Peng","family":"Yong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hon Lyn","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Muro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Lordick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zev","family":"Wainburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo Chuan","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guowei","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Suda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Law","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Sano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramesh","family":"Gurunathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emile","family":"Woo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuong","family":"Duong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-Kwang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vo Duy","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyung Ho","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han Alexander","family":"Mahendren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyuk Joon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inian","family":"Samarasam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuji","family":"Gotoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reis","family":"Liew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asim","family":"Shabbir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myint Oo","family":"Aung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Terashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Cheong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9772-7905","authenticated-orcid":false,"given":"Jimmy","family":"So","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,13]]},"reference":[{"issue":"7","key":"2266_CR1","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1245\/s10434-014-3608-7","volume":"21","author":"JH Shim","year":"2014","unstructured":"Shim JH, Song KY, Jeon HM, Park CH, Jacks LM, Gonen M, et al. Is gastric cancer different in Korea and the United States? Impact of tumor location on prognosis. Ann Surg Oncol. 2014;21(7):2332\u20139. https:\/\/doi.org\/10.1245\/s10434-014-3608-7.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"2266_CR2","doi-asserted-by":"publisher","first-page":"159","DOI":"10.5230\/jgc.2024.24.e3","volume":"24","author":"JY Park","year":"2024","unstructured":"Park JY, Kim EJ, Yang JY, Park KB, Kwon OK. Comparison of the prognosis of upper-third gastric cancer with that of middle and lower-third gastric cancer. J Gastric Cancer. 2024;24(2):159\u201371. https:\/\/doi.org\/10.5230\/jgc.2024.24.e3.","journal-title":"J Gastric Cancer"},{"issue":"2","key":"2266_CR3","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s10120-011-0041-5","volume":"14","author":"T Sano","year":"2011","unstructured":"Sano T, Kodera Y. Japanese classification of gastric carcinoma 3rd English edition. Gastric Cancer. 2011;14(2):101\u201312.","journal-title":"Gastric Cancer"},{"issue":"2","key":"2266_CR4","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/anae.15808","volume":"78","author":"LC Savic","year":"2023","unstructured":"Savic LC, Smith AF. How to conduct a Delphi consensus process. Anaesthesia. 2023;78(2):247\u201350.","journal-title":"Anaesthesia"},{"issue":"4","key":"2266_CR5","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","volume":"64","author":"H Balshem","year":"2011","unstructured":"Balshem H, Helfand M, Sch\u00fcnemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64(4):401\u20136.","journal-title":"J Clin Epidemiol"},{"key":"2266_CR6","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.annonc.2024.11.016","volume":"36","author":"A Raimondi","year":"2024","unstructured":"Raimondi A, Lonardi S, Murgioni S, Cardellino GG, Tamberi S, Strippoli A, et al. Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INFINITY study by GONO. Ann Oncol. 2024;36:285\u201396. https:\/\/doi.org\/10.1016\/j.annonc.2024.11.016.","journal-title":"Ann Oncol"},{"issue":"3","key":"2266_CR7","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s10120-024-01471-z","volume":"27","author":"Z Jiang","year":"2024","unstructured":"Jiang Z, Xie Y, Zhang W, Du C, Zhong Y, Zhu Y, et al. Perioperative chemotherapy with docetaxel plus oxaliplatin and S-1 (DOS) versus oxaliplatin plus S-1 (SOX) for the treatment of locally advanced gastric or gastro-esophageal junction adenocarcinoma (MATCH): an open-label, randomized, phase 2 clinical trial. Gastric Cancer. 2024;27(3):571\u20139.","journal-title":"Gastric Cancer"},{"issue":"S1","key":"2266_CR8","doi-asserted-by":"publisher","first-page":"S879","DOI":"10.1016\/j.annonc.2024.08.1468","volume":"37","author":"D Liu","year":"2024","unstructured":"Liu D, Hall MK, Wong D, Lee M, Duong C, Bright T, et al. 754. Pathological response predicts efficacy of adjuvant flot chemotherapy in gastroesophageal cancer: an International Cohort Study. Dis Esophagus. 2024;37(S1):S879. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.1468.","journal-title":"Dis Esophagus"},{"issue":"17_suppl","key":"2266_CR9","doi-asserted-by":"publisher","first-page":"LBA1","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA1","volume":"42","author":"J Hoeppner","year":"2024","unstructured":"Hoeppner J, Brunner T, Lordick F, Schmoor C, Kulemann B, Neumann UP, et al. Prospective randomized multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (ESOPEC trial). J Clin Oncol. 2024;42(17_suppl):LBA1. https:\/\/doi.org\/10.1200\/JCO.2024.42.17_suppl.LBA1.","journal-title":"J Clin Oncol"},{"issue":"19","key":"2266_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJMoa2405195","volume":"391","author":"T Leong","year":"2024","unstructured":"Leong T, Smithers BM, Michael M, Haustermans K, Wong R, Gebski V, et al. Preoperative chemoradiotherapy for resectable gastric cancer. N Engl J Med. 2024;391(19):1\u201312. https:\/\/doi.org\/10.1056\/NEJMoa2405195.","journal-title":"N Engl J Med"},{"issue":"4","key":"2266_CR11","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1007\/s10120-024-01506-5","volume":"27","author":"K Furukawa","year":"2024","unstructured":"Furukawa K, Hatakeyama K, Terashima M, Urakami K, Koseki Y, Fujiya K, et al. Molecular features and prognostic factors of locally advanced microsatellite instability-high gastric cancer. Gastric Cancer. 2024;27(4):760\u201371. https:\/\/doi.org\/10.1007\/s10120-024-01506-5.","journal-title":"Gastric Cancer"},{"key":"2266_CR12","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s00464-024-11427-0","volume":"39","author":"T Tanaka","year":"2024","unstructured":"Tanaka T, Suda K, Nakauchi M, Fujita M, Suzuki K, Umeki Y, et al. Safety and feasibility of laparoscopic stomach-partitioning gastrojejunostomy combined with neoadjuvant chemotherapy followed by minimally invasive gastrectomy for resectable gastric cancer with gastric outlet obstruction. Surg Endosc. 2024;39:837\u201349.","journal-title":"Surg Endosc"},{"issue":"16_suppl","key":"2266_CR13","doi-asserted-by":"publisher","first-page":"4067","DOI":"10.1200\/JCO.2023.41.16_suppl.4067","volume":"41","author":"YK Kang","year":"2023","unstructured":"Kang YK, Kim HD, Yook JH, Park YK, Kim YW, Kim JY, et al. Neoadjuvant docetaxel, oxaliplatin, and s-1 plus surgery and adjuvant s-1 for resectable advanced gastric cancer: Final survival outcomes of the randomized phase 3 PRODIGY trial. J Clin Oncol. 2023;41(16_suppl):4067.","journal-title":"J Clin Oncol"},{"issue":"8","key":"2266_CR14","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/S1470-2045(21)00297-7","volume":"22","author":"X Zhang","year":"2021","unstructured":"Zhang X, Liang H, Li Z, Xue Y, Wang Y, Zhou Z, et al. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial. Lancet Oncol. 2021;22(8):1081\u201392.","journal-title":"Lancet Oncol"},{"issue":"4","key":"2266_CR15","doi-asserted-by":"publisher","first-page":"239","DOI":"10.4103\/0971-5851.144970","volume":"35","author":"SV Shrikhande","year":"2014","unstructured":"Shrikhande SV, Sirohi B, Barreto SG, Chacko RT, Parikh PM, Pautu J, et al. Indian Council of Medical Research consensus document for the management of gastric cancer. Indian J Med Paediatr Oncol. 2014;35(4):239\u201343.","journal-title":"Indian J Med Paediatr Oncol"},{"issue":"7","key":"2266_CR16","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1002\/jso.26177","volume":"122","author":"AN Blumenthaler","year":"2020","unstructured":"Blumenthaler AN, Ikoma N, Blum M, Das P, Minsky BD, Mansfield PF, et al. Relationship between initial management strategy and survival in patients with gastric outlet obstruction due to gastric cancer. J Surg Oncol. 2020;122(7):1373\u201382.","journal-title":"J Surg Oncol"},{"key":"2266_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30321-2","volume":"18","author":"M Das","year":"2017","unstructured":"Das M. Neoadjuvant chemotherapy: survival benefit in gastric cancer. Lancet Oncol. 2017;18: e307.","journal-title":"Lancet Oncol"},{"issue":"5","key":"2266_CR18","first-page":"534","volume":"6","author":"AD Newton","year":"2015","unstructured":"Newton AD, Datta J, Loaiza-Bonilla A, Karakousis GC, Roses RE. Neoadjuvant therapy for gastric cancer: Current evidence and future directions. J Gastrointest Oncol. 2015;6(5):534\u201343.","journal-title":"J Gastrointest Oncol"},{"issue":"6","key":"2266_CR19","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1002\/bjs.9484","volume":"101","author":"A Tsuburaya","year":"2014","unstructured":"Tsuburaya A, Mizusawa J, Tanaka Y, Fukushima N, Nashimoto A, Sasako M. Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis. Br J Surg. 2014;101(6):653\u201360. https:\/\/doi.org\/10.1002\/bjs.9484.","journal-title":"Br J Surg"},{"issue":"2","key":"2266_CR20","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1007\/s10120-023-01453-7","volume":"27","author":"Y Kurokawa","year":"2024","unstructured":"Kurokawa Y, Doki Y, Kitabayashi R, Yoshikawa T, Nomura T, Tsuji K, et al. Short-term outcomes of preoperative chemotherapy with docetaxel, oxaliplatin, and S-1 for gastric cancer with extensive lymph node metastasis (JCOG1704). Gastric Cancer. 2024;27(2):366\u201374. https:\/\/doi.org\/10.1007\/s10120-023-01453-7.","journal-title":"Gastric Cancer"},{"issue":"2","key":"2266_CR21","doi-asserted-by":"publisher","first-page":"102226","DOI":"10.1016\/j.esmoop.2023.102226","volume":"9","author":"K Shitara","year":"2024","unstructured":"Shitara K, Fleitas T, Kawakami H, Curigliano G, Narita Y, Wang F, et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer. ESMO Open. 2024;9(2):102226. https:\/\/doi.org\/10.1016\/j.esmoop.2023.102226.","journal-title":"ESMO Open"},{"issue":"5","key":"2266_CR22","doi-asserted-by":"publisher","first-page":"2831","DOI":"10.1245\/s10434-020-09403-8","volume":"28","author":"MR Ju","year":"2021","unstructured":"Ju MR, Karalis JD, Blackwell JM, Mansour JC, Polanco PM, Augustine M, et al. Inaccurate clinical stage is common for gastric adenocarcinoma and is associated with undertreatment and worse outcomes. Ann Surg Oncol. 2021;28(5):2831\u201343. https:\/\/doi.org\/10.1245\/s10434-020-09403-8.","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"2266_CR23","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1002\/jso.27233","volume":"127","author":"LM Janczewski","year":"2023","unstructured":"Janczewski LM, Shah D, Wells A, Bentrem DJ, Abad JD, Chawla A. The inaccuracies of gastric adenocarcinoma clinical staging and its predictive factors. J Surg Oncol. 2023;127(7):1116\u201324. https:\/\/doi.org\/10.1002\/jso.27233.","journal-title":"J Surg Oncol"},{"issue":"1","key":"2266_CR24","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s10120-017-0701-1","volume":"21","author":"T Fukagawa","year":"2018","unstructured":"Fukagawa T, Katai H, Mizusawa J, Nakamura K, Sano T, Terashima M, et al. A prospective multi-institutional validity study to evaluate the accuracy of clinical diagnosis of pathological stage III gastric cancer (JCOG1302A). Gastric Cancer. 2018;21(1):68\u201373. https:\/\/doi.org\/10.1007\/s10120-017-0701-1.","journal-title":"Gastric Cancer"},{"issue":"1","key":"2266_CR25","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s13045-017-0517-9","volume":"10","author":"B Badgwell","year":"2017","unstructured":"Badgwell B, Das P, Ajani J. Treatment of localized gastric and gastroesophageal adenocarcinoma: The role of accurate staging and preoperative therapy. J Hematol Oncol. 2017;10(1):149.","journal-title":"J Hematol Oncol"},{"issue":"07","key":"2266_CR26","doi-asserted-by":"publisher","first-page":"100829","DOI":"10.1016\/j.ctarc.2024.100829","volume":"40","author":"MS Wagh","year":"2024","unstructured":"Wagh MS, Balan AK, Mathew AP, Rakesh CA, Krishna J, Chandramohan K, et al. Sarcopenia in gastric cancer and its impact on early postoperative outcome. Cancer Treat Res Commun. 2024;40(07):100829. https:\/\/doi.org\/10.1016\/j.ctarc.2024.100829.","journal-title":"Cancer Treat Res Commun"},{"issue":"3","key":"2266_CR27","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3390\/biomedicines7030054","volume":"7","author":"H Kawabata","year":"2019","unstructured":"Kawabata H, Hitomi M, Motoi S. Management of bleeding from unresectable gastric cancer. Biomedicines. 2019;7(3):54.","journal-title":"Biomedicines"},{"issue":"1","key":"2266_CR28","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.gie.2013.03.006","volume":"78","author":"S Leblanc","year":"2013","unstructured":"Leblanc S, Vienne A, Dhooge M, Coriat R, Chaussade S, Prat F. Early experience with a novel hemostatic powder used to treat upper GI bleeding related to malignancies or after therapeutic interventions (with videos). Gastrointest Endosc. 2013;78(1):169\u201375.","journal-title":"Gastrointest Endosc"},{"issue":"16","key":"2266_CR29","doi-asserted-by":"publisher","first-page":"5731","DOI":"10.1002\/cam4.3224","volume":"9","author":"Q Zhao","year":"2020","unstructured":"Zhao Q, Lian C, Huo Z, Li M, Liu Y, Fan L, et al. The efficacy and safety of neoadjuvant chemotherapy on patients with advanced gastric cancer: A multicenter randomized clinical trial. Cancer Med. 2020;9(16):5731\u201345.","journal-title":"Cancer Med"},{"issue":"11","key":"2266_CR30","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/S2468-1253(23)00243-1","volume":"8","author":"JV Reynolds","year":"2023","unstructured":"Reynolds JV, Preston SR, O\u2019Neill B, Lowery MA, Baeksgaard L, Crosby T, et al. Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial. Lancet Gastroenterol Hepatol. 2023;8(11):1015\u201327. https:\/\/doi.org\/10.1016\/S2468-1253(23)00243-1.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10184","key":"2266_CR31","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"SE Al-Batran","year":"2019","unstructured":"Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a ra. Lancet. 2019;393(10184):1948\u201357.","journal-title":"Lancet"},{"issue":"2","key":"2266_CR32","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.0426","volume":"5","author":"J Yu","year":"2022","unstructured":"Yu J, Gao Y, Chen L, Wu D, Shen Q, Zhao Z, et al. Effect of S-1 plus oxaliplatin compared with fluorouracil, leucovorin plus oxaliplatin as perioperative chemotherapy for locally advanced, resectable gastric cancer: a randomized clinical trial. JAMA Netw Open. 2022;5(2): e220426.","journal-title":"JAMA Netw Open"},{"issue":"4","key":"2266_CR33","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1159\/000078326","volume":"66","author":"K Higuchi","year":"2004","unstructured":"Higuchi K, Koizumi W, Tanabe S, Saigenji K, Ajani JA. Chemotherapy is more active against proximal than distal gastric carcinoma. Oncology. 2004;66(4):269\u201374.","journal-title":"Oncology"},{"key":"2266_CR34","first-page":"383","volume":"7","author":"S Antoun","year":"2013","unstructured":"Antoun S, Borget I, Lanoy E. Impact of sarcopenia on the prognosis and treatment toxicities in patients diagnosed with cancer. Curr Opin Support Pall Care. 2013;7:383\u20139.","journal-title":"Curr Opin Support Pall Care"},{"issue":"1","key":"2266_CR35","doi-asserted-by":"publisher","first-page":"32041","DOI":"10.1056\/NEJM199507063330107","volume":"333","author":"CS Fuchs","year":"1995","unstructured":"Fuchs CS, Mayer RJ. Gastric carcinoma. N Engl J Med. 1995;333(1):32041.","journal-title":"N Engl J Med"},{"key":"2266_CR36","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12957-021-02126-4","volume":"19","author":"J Xue","year":"2021","unstructured":"Xue J, Yang H, Huang S, Zhou T, Zhang X, Zu G. Comparison of the overall survival of proximal and distal gastric cancer after gastrectomy: a systematic review and meta-analysis. World J Surg Oncol. 2021;19:17.","journal-title":"World J Surg Oncol"},{"issue":"9","key":"2266_CR37","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1001\/jamaoncol.2016.6762","volume":"3","author":"EC Smyth","year":"2017","unstructured":"Smyth EC, Wotherspoon A, Peckitt C, Gonzalez D, Hulkki-Wilson S, Eltahir Z, et al. Mismatch repair deficiency, microsatellite instability, and survival: An exploratory analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial. JAMA Oncol. 2017;3(9):1197\u2013203.","journal-title":"JAMA Oncol"},{"issue":"9813","key":"2266_CR38","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/S0140-6736(11)61873-4","volume":"379","author":"YJ Bang","year":"2012","unstructured":"Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): A phase 3 open-label, randomised controlled trial. Lancet. 2012;379(9813):315\u201321.","journal-title":"Lancet"},{"issue":"4","key":"2266_CR39","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1245\/s10434-021-11050-6","volume":"29","author":"RC Nie","year":"2022","unstructured":"Nie RC, Chen GM, Yuan SQ, Kim JW, Zhou J, Nie M, et al. Adjuvant chemotherapy for gastric cancer patients with mismatch repair deficiency or microsatellite instability: systematic review and meta-analysis. Ann Surg Oncol. 2022;29(4):2324\u201331. https:\/\/doi.org\/10.1245\/s10434-021-11050-6.","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"2266_CR40","first-page":"1178","volume":"52","author":"JW Kim","year":"2020","unstructured":"Kim JW, Cho SY, Chae J, Kim JW, Kim TY, Lee KW, et al. Adjuvant chemotherapy in microsatellite instability\u2013high gastric cancer. Cancer Res Treat. 2020;52(4):1178\u201387.","journal-title":"Cancer Res Treat"},{"issue":"2","key":"2266_CR41","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1200\/JCO.22.00686","volume":"41","author":"T Andr\u00e9","year":"2023","unstructured":"Andr\u00e9 T, Tougeron D, Piessen G, De La Fouchardi\u00e8re C, Louvet C, Adenis A, et al. Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair\/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma: the GERCOR NEONIPIGA Phase II Study. J Clin Oncol. 2023;41(2):255\u201365.","journal-title":"J Clin Oncol"},{"issue":"2","key":"2266_CR42","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/S1470-2045(23)00541-7","volume":"25","author":"K Shitara","year":"2024","unstructured":"Shitara K, Rha SY, Wyrwicz LS, Oshima T, Karaseva N, Osipov M, et al. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study. Lancet Oncol. 2024;25(2):212\u201324.","journal-title":"Lancet Oncol"},{"issue":"20","key":"2266_CR43","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.2217\/fon-2022-0093","volume":"18","author":"YY Janjigian","year":"2022","unstructured":"Janjigian YY, Van Cutsem E, Muro K, Wainberg Z, Al-Batran SE, Hyung WJ, et al. MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric\/gastroesophageal junction cancer. Futur Oncol. 2022;18(20):2465\u201373.","journal-title":"Futur Oncol"},{"issue":"16_suppl","key":"2266_CR44","doi-asserted-by":"publisher","first-page":"4000","DOI":"10.1200\/JCO.2023.41.16_suppl.4000","volume":"41","author":"M Terashima","year":"2023","unstructured":"Terashima M, Kang YK, Kim YW, Boku N, Chung HCC, Chen JS, et al. ATTRACTION-5: A phase 3 study of nivolumab plus chemotherapy as postoperative adjuvant treatment for pathological stage III (pStage III) gastric or gastroesophageal junction (G\/GEJ) cancer. J Clin Oncol. 2023;41(16_suppl):4000.","journal-title":"J Clin Oncol"},{"key":"2266_CR45","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.3389\/fonc.2019.01320","volume":"9","author":"E Smyth","year":"2020","unstructured":"Smyth E, Kn\u00f6dler M, Giraut A, Mauer M, Nilsson M, Van Grieken N, et al. VESTIGE: adjuvant immunotherapy in patients with resected esophageal, gastroesophageal junction and gastric cancer following preoperative chemotherapy with high risk for recurrence (N+ and\/or R1): an open label randomized controlled phase-2-study. Front Oncol. 2020;9:1320.","journal-title":"Front Oncol"},{"key":"2266_CR46","doi-asserted-by":"publisher","first-page":"S852","DOI":"10.1016\/j.annonc.2023.09.1425","volume":"34","author":"C Li","year":"2023","unstructured":"Li C, Zheng Y, Shi Z, Yang L, Zhang B, Wang Z, et al. 1512MO Perioperative camrelizumab (C) combined with rivoceranib (R) and chemotherapy (chemo) versus chemo for locally advanced resectable gastric or gastroesophageal junction (G\/GEJ) adenocarcinoma: The first interim analysis of a randomized, phase III tr. Ann Oncol. 2023;34:S852.","journal-title":"Ann Oncol"},{"issue":"3_supppl","key":"2266_CR47","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1200\/JCO.2024.42.3_suppl.361","volume":"42","author":"N Semenov","year":"2024","unstructured":"Semenov N, Dalgatov K, Izrailov R, Zhukova L. FLOT compared to FOLFOX\/XELOX as a neoadjuvant chemotherapy in locally advanced gastric cancer: Experience of two clinics. J Clin Oncol. 2024;42(3_supppl):361.","journal-title":"J Clin Oncol"},{"issue":"7","key":"2266_CR48","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1177\/0003134820972083","volume":"87","author":"C Kaltenmeier","year":"2021","unstructured":"Kaltenmeier C, Althans A, Mascara M, Nassour I, Khan S, Hoehn R, et al. Pathologic complete response following neoadjuvant therapy for gastric adenocarcinoma: a national cancer database analysis on incidence, predictors, and outcomes. Am Surg. 2021;87(7):1145\u201354.","journal-title":"Am Surg"},{"issue":"2","key":"2266_CR49","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1002\/prm2.12038","volume":"10","author":"Q Hu","year":"2021","unstructured":"Hu Q, Wang J, Xu W, Shao P, Li G. Survival outcomes of locally advanced gastric cancer cases with pathological complete response received neoadjuvant chemotherapy. Precis Med Sci. 2021;10(2):78\u201382.","journal-title":"Precis Med Sci"},{"issue":"6","key":"2266_CR50","doi-asserted-by":"publisher","first-page":"621","DOI":"10.4103\/1735-5362.359430","volume":"17","author":"P Farrokhi","year":"2022","unstructured":"Farrokhi P, Sadeghi A, Sharifi M, Riechelmann R, Moghaddas A. Efficacy and safety of FLOT regimen vs DCF, FOLFOX, and ECF regimens as perioperative chemotherapy treatments for resectable gastric cancer patients; a report from the middle east. Res Pharm Sci. 2022;17(6):621\u201334.","journal-title":"Res Pharm Sci"},{"issue":"7","key":"2266_CR51","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.1007\/s00432-022-04283-9","volume":"149","author":"M Davern","year":"2023","unstructured":"Davern M, Donlon NE, Sheppard AS, Majcher KD, Connell FO, Heeran AB, et al. FLOT and CROSS chemotherapy regimens alter the frequency of CD27+ and CD69+ T cells in oesophagogastric adenocarcinomas: implications for combination with immunotherapy. J Cancer Res Clin Oncol. 2023;149(7):3753\u201374.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"5","key":"2266_CR52","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.21873\/invivo.12979","volume":"36","author":"N Takahashi","year":"2022","unstructured":"Takahashi N, Ando T, Motoo I, Sakumura M, Ueda Y, Kajiura S, et al. Efficacy and Safety of FOLFOX in Advanced Gastric Cancer Initially Presenting With Disseminated Intravascular Coagulation. In Vivo (Brooklyn). 2022;36(5):2447\u201352.","journal-title":"In Vivo (Brooklyn)"},{"issue":"12","key":"2266_CR53","first-page":"7037","volume":"37","author":"T Masuishi","year":"2017","unstructured":"Masuishi T, Kadowaki S, Kondo M, Komori A, Sugiyama K, Mitani S, et al. FOLFOX as first-line therapy for gastric cancer with severe peritoneal metastasis. Anticancer Res. 2017;37(12):7037\u201342.","journal-title":"Anticancer Res"},{"issue":"6","key":"2266_CR54","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1001\/jamaoncol.2015.2378","volume":"1","author":"HG Prigerson","year":"2015","unstructured":"Prigerson HG, Bao Y, Shah MA, Elizabeth Paulk M, LeBlanc TW, Schneider BJ, et al. Chemotherapy use, performance status, and quality of life at the end of life. JAMA Oncol. 2015;1(6):778\u201384.","journal-title":"JAMA Oncol"},{"issue":"2","key":"2266_CR55","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.clon.2004.10.006","volume":"17","author":"D Wilson","year":"2005","unstructured":"Wilson D, Hiller L, Geh JI. Review of second-line chemotherapy for advanced gastric adenocarcinoma. Clin Oncol. 2005;17(2):81\u201390.","journal-title":"Clin Oncol"},{"issue":"2","key":"2266_CR56","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1159\/000481404","volume":"94","author":"T Wakahara","year":"2018","unstructured":"Wakahara T, Ueno N, Maeda T, Kanemitsu K, Yoshikawa T, Tsuchida S, et al. Impact of gastric cancer surgery in elderly patients. Oncol. 2018;94(2):79\u201384.","journal-title":"Oncol"},{"issue":"4","key":"2266_CR57","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.amjsurg.2020.03.006","volume":"221","author":"J Schendel","year":"2021","unstructured":"Schendel J, Jost E, Mah M, Mack L, McCall M, Gu N, et al. Gastric cancer management in elderly patients: a population-based study of treatment patterns and outcomes in gastric cancer patients \u2265 75 years from Alberta. Canada Am J Surg. 2021;221(4):839\u201343.","journal-title":"Canada Am J Surg"},{"issue":"1","key":"2266_CR58","doi-asserted-by":"publisher","first-page":"33","DOI":"10.4235\/agmr.21.0144","volume":"26","author":"Y Choi","year":"2022","unstructured":"Choi Y, Kim N, Kim KW, Jo HH, Park J, Yoon H, et al. Gastric cancer in older patients: a retrospective study and literature review. Ann Geriatr Med Res. 2022;26(1):33\u201341.","journal-title":"Ann Geriatr Med Res"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-025-02266-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-025-02266-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-025-02266-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T19:29:54Z","timestamp":1757186994000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00535-025-02266-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,13]]},"references-count":58,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["2266"],"URL":"https:\/\/doi.org\/10.1007\/s00535-025-02266-4","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,13]]},"assertion":[{"value":"21 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors. the undersigned authors warrant that the article is original, is not under consideration by another journal, and has not been published previously.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}